Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV).
暂无分享,去创建一个
M. Juan | L. Badimón | A. Zapata | J. Bueren | F. Sánchez-Guijo | D. García-Olmo | J. Pérez-Simón | M. Fernández-Santos | A. Sureda | Á. Urbano-Ispizua | C. Eguizabal | A. Pérez‐Martínez | C. Avendaño-Solá | Julio Delgado | J. M. Canals | R. Mata | Nuria Montserrat | F. Prósper | J. Moraleda | Joaquim Delgadillo | Cristina Avendaño-Solá | Fermín Sánchez-Guijo | Lina Badimón | Juan A Bueren | Gloria González-Aseguinolaza | Manel Juan | Francisco Martín | Nuria Montserrat | Felipe Prósper | Álvaro Urbano-Ispizua | Francisco Martín
[1] A. Schambach,et al. Access to gene therapy for rare diseases when commercialization is not fit for purpose , 2023, Nature Medicine.
[2] Patricia J. Zettler,et al. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. , 2022, Cytotherapy.
[3] M. Juan,et al. Is Hospital Exemption an alternative or a bridge to EMA for developing Academic CAR-T in Europe? Our experience with ARI0001. , 2021, Human gene therapy.
[4] J. García-Sancho,et al. Spanish Cell Therapy Network (TerCel): 15 years of successful collaborative translational research. , 2019, Cytotherapy.